Results 81 to 90 of about 28,388 (258)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus

Diabetes, Metabolic Syndrome and Obesity, 2010
Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes.
Kushner P
doaj   +2 more sources

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors

Drug Design, Development and Therapy, 2015
Watshara Shoombuatong,1 Veda Prachayasittikul,1,2 Nuttapat Anuwongcharoen,1 Napat Songtawee,1 Teerawat Monnor,1 Supaluk Prachayasittikul,1 Virapong Prachayasittikul,2 Chanin Nantasenamat1,2 1Center of Data Mining and Biomedical Informatics, 2Department ...
Shoombuatong W, Prachayasittikul V, Anuwongcharoen N, Songtawee N, Monnor T, Prachayasittikul S, Prachayasittikul V, Nantasenamat C   +7 more
doaj  

Alogliptin benzoate for management of type 2 diabetes

Vascular Health and Risk Management, 2015
Yoshifumi Saisho Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress ...
Saisho Y
doaj  

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South
Sungho Bea, Hyesung Lee, Young Min Cho, You‐Jung Choi, Ju‐Young Shin, Katsiaryna Bykov   +5 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor [PDF]

, 2020
openaire   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source

Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four Cases

Medeniyet Medical Journal
Dipeptidyl-peptidase 4 inhibitors (DPP4i) are commonly used as antidiabetic medications. Although these drugs are generally recognized for their favorable clinical safety profile, emerging evidence points to the potential for adverse events associated ...
Neslihan USLU, Kagan GUNGOR, Gonca TAMER, Bulent CAN   +3 more
doaj   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid, [PDF]

Anais Brasileiros de Dermatologia, 2022
Agoritsa Gravani, Panagiota Christou, Stelios Tigas, Ioannis D. Bassukas   +3 more
doaj   +1 more source